0611/26SCR019-18/R6RGB
Media Highlights
From the 2026 ASCO® Annual Meeting
7
David Spigel, MD
SCRI
Media Outlet Date Article / Coverage
Apex Onco 5/31/26 ASCO 2026 – Ivonescimab Blows Tevimbra Out of the Water
BioSpace 5/31/26 ASCO: Akeso's VEGF/PD-1 Boosts Lung Cancer Survival,
Relieving Pressure on US Partner Summit
Cure Today 6/3/26 Top 5 Takeaways From ASCO 2026 That Patients
Should Know
eCancer 5/31/26 ASCO 2026: Ivonescimab May Improve Overall Survival
in Patients With Advanced Squamous Non-Small Cell
Lung Cancer
Endpoints 5/31/26 Summit, Akeso Drug Reduces Death by 34% in China Lung
Cancer Study. Here's What It Means
Fierce Biotech 5/30/26 In Next-Gen IO Race in NSCLC, BioNTech/BMS and Pfizer Are
Divided on Overall Survival Approach
Fierce Pharma 5/31/26 ASCO: Akeso's Ivonescimab Bests PD-1 inhibitor in Lung
Cancer Chemo Combos, Slashing Death Risk by 34%
FirstWord Pharma 5/31/26 ASCO26: Lilly Details "Practice Changing" Data for RET
inhibitor in Earlier Stage Lung Cancer
FirstWord Pharma 5/31/26 ASCO26: Summit, Akeso Claim OS Victory for Ivonescimab in
Pivotal Chinese Study
HealthDay 6/2/26 ASCO: Selpercatinib Improves Event-Free Survival in RET
Fusion-Positive NSCLC
Managed Healthcare
Executive
5/31/26 Ivonescimab Reduced the Risk of Death By 34% In Squamous
NSCLC | ASCO 2026
MedPage Today 5/31/26 'Immediately Practice-Changing' Lung Cancer Trial
in Curative Setting
MedPage Today 5/31/26 Upfront Ivonescimab Plus Chemo Bests PD-1 Inhibitor Combo
in Advanced NSCLC
Medscape 5/31/26 Selpercatinib Cuts Recurrence Risk in Early RET+ Non-Small
Cell Lung Cancer
Medscape 6/1/26 Trial Supports Ivonescimab and Chemo for NSCLC Survival
Continued ➔
